Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - Cancer research, 2015 - AACR
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …
被引用次数：87 相关文章

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - CANCER …, 2015 - air.unipr.it
Abstract Mutated KRAS (KRAS∗) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS∗-driven PDAC, we …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah… - Cancer …, 2015 - mdanderson.elsevierpure.com
Abstract Mutated KRAS (KRAS∗) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS∗-driven PDAC, we …
[HTML] nih.gov

[HTML][HTML] Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - Cancer …, 2015 - ncbi.nlm.nih.gov
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah, A Carugo… - Cancer …, 2015 - pubmed.ncbi.nlm.nih.gov
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …

Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - Cancer …, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Mutated KRAS (KRAS*) is a fundamental
driver in the majority of pancreatic ductal adenocarcinomas (PDAC). Using an inducible …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - Cancer …, 2015 - europepmc.org
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah, A Carugo… - Cancer …, 2015 - ohsu.elsevierpure.com
Abstract Mutated KRAS (KRAS∗) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS∗-driven PDAC, we …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer

P Pettazzoni, A Viale, P Shah… - Cancer …, 2015 - utsouthwestern.elsevierpure.com
Abstract Mutated KRAS (KRAS∗) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS∗-driven PDAC, we …

Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.

P Pettazzoni, A Viale, P Shah, A Carugo, H Ying… - Cancer …, 2015 - europepmc.org
Mutated KRAS (KRAS*) is a fundamental driver in the majority of pancreatic ductal
adenocarcinomas (PDAC). Using an inducible mouse model of KRAS*-driven PDAC, we …